Rating: irA- (KRI)
Pharma Turnaround Hits Operating Breakeven as Pyridam Terms Out Its 2027 Maturity
PT Pyridam Farma Tbk (IDX: PYFA) is an integrated pharmaceutical group, founded in 1976 and listed in 2001, spanning prescription medicines, consumer health, esthetics, medical devices and contract manufacturing (CDMO) across Indonesia and Australia. It has expanded since 2021 through the acquisitions of Holi Pharma, Ethica Industri Farmasi and, in June 2024, Probiotec of Australia (AUD165mn, about IDR2.7tn), and now consolidates nine entities across Indonesia, Singapore and Australia. Held 60.20% by Singapore-based Rejuve Global Investment Pte Ltd, the controlling shareholder since July 2020.
Indicative Structure
- Obligasi: up to IDR770.0bn – single series, 5Y
- Coupon: 9.50% p.a. fixed, paid quarterly.
- Clean basis (unsecured), bullet repayment at maturity.
- Proceeds fund: around IDR400.0bn to refinance the PUB I Tahap I 2022 bond maturing 8 Mar 2027; the balance (around IDR370.0bn) for working capital.
- Part of PUB II (target IDR1.5tn; Tahap I placed IDR420.0bn in July 2025), Tahap II.
Why This Deal
- Turnaround now visible. 1H2026 revenue rose 16.8% yoy to IDR1,617.5bn, gross margin widened 180bp to 23.1% and the operating line reached breakeven. Australia contributes 73% of revenue, giving a partial FX hedge.
- Attractive carry. The 9.50% coupon pays about 60bp over the idA- 5-year curve and roughly 250bp over the 5-year SBN. We recommend SUBSCRIBE.
- Parent support offsets high leverage. Rejuve has issued a financial support letter, and proceeds refinance the March 2027 maturity. Net debt/EBITDA of 16.2x and negative operating cash flow remain the watch items.
Indicative Timeline
- Bookbuilding 1 – 13 Oct 2026
- Public Offering 2 – 3 Nov 2026
- Allotment 4 Nov 2026 · Listing IDX 9 Nov 2026
Regards, Aldiracita Research